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Abstract Signaling by mTOR complex 1 (mTORC1)
promotes anabolic cellular processes in response to growth
factors, nutrients, and hormonal cues. Numerous clinical
trials employing the mTORC1 inhibitor rapamycin (aka
sirolimus) to immuno-suppress patients following organ
transplantation have documented the development of
hypertriglyceridemia and elevated serum free fatty acids
(FFA). We therefore investigated the cellular role of
mTORC1 in control of triacylglycerol (TAG) metabolism
using cultured murine 3T3-L1 adipocytes. We found that
treatment of adipocytes with rapamycin reduced insulin-
stimulated TAG storage *50%. To determine whether
rapamycin reduces TAG storage by upregulating lipolytic
rate, we treated adipocytes in the absence and presence of
rapamycin and isoproterenol, a b2-adrenergic agonist that
activates the cAMP/protein kinase A (PKA) pathway to
promote lipolysis. We found that rapamycin augmented
isoproterenol-induced lipolysis without altering cAMP
levels. Rapamycin enhanced the isoproterenol-stimulated
phosphorylation of hormone sensitive lipase (HSL) on Ser-
563 (a PKA site), but had no effect on the phosphorylation
of HSL S565 (an AMPK site). Additionally, rapamycin did
not affect the isoproterenol-mediated phosphorylation of
perilipin, a protein that coats the lipid droplet to initiate
lipolysis upon phosphorylation by PKA. These data dem-
onstrate that inhibition of mTORC1 signaling synergizes
with the b-adrenergic-cAMP/PKA pathway to augment
phosphorylation of HSL to promote hormone-induced
lipolysis. Moreover, they reveal a novel metabolic function
for mTORC1; mTORC1 signaling suppresses lipolysis,
thus augmenting TAG storage.
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GbL G protein b subunit-like protein also
known as mLST8
GLUT 4 Glucose transporter 4
IRS Insulin receptor substrate
LKB Tumor suppressor protein
LPAAT Lysophosphatidic acid acyl transferase
MEFs Mouse embryonic fibroblasts
MGL Monoacylglycerol lipase
mTOR Mammalian target of rapamycin (TOR)
mTOR P-S2481 mTOR phosphorylated on serine 2481
mTORC1 Mammalian target of rapamycin
complex 1
mTORC2 Mammalian target of rapamycin
complex 2
NCS Newborn calf serum
NEFA Nonesterified fatty acids
RAPA Rapamycin
Raptor Regulatory associated protein of
mammalian target of rapamycin
Rheb Ras homolog enriched in brain
Rictor Rapamycin-insensitive companion of
mTOR
RII Regulatory subunit II of PKA




PI3K Phosphatidylinositol 3-OH kinase
Pol I Polymerase I
PKA Protein kinase A
PKB/AKT Protein kinase B
PPAR c Peroxisome proliferator-activated
receptor-c
PTEN Phosphatase and tensin homologue
deleted on chromosome 10
S6K1 p70 ribosomal protein S6 kinase 1
S6K1 P-T389 S6K1 phosphorylated on threonine 389
TAG Triacylglycerol
TSC Tuberous sclerosis complex
VLDL Very low density lipoprotein
Introduction
The mammalian target of rapamycin (mTOR), an evolu-
tionarily conserved Ser/Thr protein kinase, coordinates a
signal transduction network that controls a plethora of
fundamental cellular functions [1–3]. mTOR forms the
catalytic core of at least two functionally distinct signaling
complexes, mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2) [3]. The better-understood complex,
mTORC1, functions as an environmental sensor to promote
anabolic cellular processes such as ribosomal gene tran-
scription, protein synthesis, lipid synthesis, cell growth/
size, and cell proliferation in response to sufficient levels of
growth factors, nutrients, and hormones [2, 3]. Conversely,
adverse cellular conditions rapidly downregulate mTORC1
signaling to promote catabolic functions such as autophagy
[4]. mTORC1 and mTORC2 contain shared and unique
partner proteins, possess unique cellular functions, and
exhibit differing sensitivities to rapamycin, a clinically
employed immunosuppressive drug [3]. Rapamycin (clin-
ically known as sirolimus) associates with a cellular protein
called FKBP12 [5]. Upon entering the cell, the rapamycin/
FKBP12 complex directly binds to the mTOR FRB
(FKBP12-rapamycin binding) domain, which lies imme-
diately N-terminal to the kinase domain [5]. Rapamycin/
FKBP12 binds assembled mTORC1 but not assembled
mTORC2 [5]. Thus, rapamycin acutely inhibits mTORC1
but not mTORC2 signaling. While the mechanisms by
which rapamycin allosterically inhibits mTORC1 signaling
remain incompletely defined, the drug reduces the affinity
between mTOR and raptor, a critical mTORC1 partner
protein [5, 6]. Additionally, rapamycin reduces mTORC1
intrinsic kinase activity, as monitored by mTOR S2481
autophosphorylation [7]. The use of rapamycin in clinical
medicine underscores the importance of mTORC1 for
organismal physiology. Not only does rapamycin reduce
organ transplant rejection [8], it reduces the intimal
de-differentiation and hyperplasia of vascular smooth muscle
cells that often follows coronary artery stent restenosis [9].
Strikingly, rapamycin extends rodent lifespan [10]. Rapa-
mycin analogs and second-generation mTOR catalytic
inhibitors also hold therapeutic promise as anti-cancer
agents [5].
Rapamycin administration incurs adverse side effects,
however. Various clinical trials have documented the
development of hypertriglyceridemia or hypercholesterol-
emia in renal, hepatic, cardiac, and islet transplant patients
[11, 12]. Additionally, rapamycin has also been shown to
elevate serum free fatty acid (FFA) levels and induce
glucose intolerance [13] in transplant patients as well as in
mice lacking the mTORC1 downstream target S6K1 [14].
Clinical trials have also documented the occurrence of
hyperlipidemia upon the administration of the rapamycin
analog CCI-779 (also known as temsirolimus; Wyeth) in
the treatment of metastatic melanoma and glioblastoma
multiforme [15]. Consistent with rapamycin increasing
levels of circulating FFAs and inducing hyperlipidemia,
mice lacking S6K1 globally or lacking raptor in adipose are
lean with reduced adipose mass and exhibit resistance to
diet-induced obesity [14]. Thus, mTORC1 inhibition
induced by pharmacological or genetic ablation disrupts
lipid homeostasis in vivo.
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In this study we set out to better understand how
mTORC1 signaling impacts lipid metabolism in cultured
adipocytes. Adipose tissue, once considered an inert energy
storage depot, is now recognized as an important metabolic
and endocrine organ that coordinates energy intake and
expenditure critical for energy homeostasis [16]. Adipose
tissue removes glucose from the circulation (via the action
of the insulin-responsive glucose transporter GLUT4) and
stores surplus energy in the form of triacylglycerol (TAG)
within lipid droplets. The tissue releases energy as needed
via the action of lipolysis, the process by which enzymes
known as lipases break down TAG into FFA and glycerol,
which are then released into the circulation. Diverse
extracellular stimuli regulate lipolysis. Catecholamines
(e.g., epinephrine) and glucocorticoids (e.g., cortisol) pro-
mote lipolysis while insulin and FFA themselves suppress
lipolysis [17]. Starvation or stress triggers the release of
catecholamines, which promote lipolysis by activating G
protein-coupled adrenergic receptors that activate adenyl-
ate cyclase (AC), which lead to increased production of
cAMP and activation of protein kinase A (PKA). Several
laboratories have established that PKA phosphorylates two
lipolytic proteins, perilipin and hormone sensitive lipase
(HSL) [18]. Perilipin functions as a master regulator of
lipolysis [19, 20]. Under basal conditions, perilipin coats
and protects lipid storage droplets. Upon agonist stimula-
tion, PKA phosphorylates perilipin A, which induces a
conformational change in the perilipin coating that enables
the recruitment of HSL from the cytoplasm to the surface
of the lipid droplet [21, 22]. Indeed, perilipin knockout
mice have reduced adipose tissue mass and exhibit elevated
basal lipolysis with resistance to b-adrenergic-stimulated
lipolysis; moreover, the mice display resistance to diet-
induced and genetic obesity [18, 22–24].
Our previous work demonstrated that rapamycin
administration induces hypertriglyceridemia in organ
transplant patients [11], and increases TAG and plasma
FFA in guinea pigs [25]. Here, we test the hypothesis that
rapamycin promotes TAG lipolysis in cultured murine
3T3-L1 adipocytes. We found that inhibition of mTORC1
signaling with rapamycin augments lipolysis promoted by
the b-adrenergic agonist isoproterenol without augmenting
cellular cAMP levels. Additionally, we found that rapa-
mycin enhances isoproterenol-induced phosphorylation of
HSL. These data indicate that mTORC1 inhibition syn-
ergizes with the PKA pathway to promote lipolysis by
modulating HSL function. Improved understanding of
how mTORC1 inhibition promotes lipolysis to disrupt
lipid metabolism may assist clinicians in the future to
better handle the deleterious side effects incurred by
therapeutic rapamycin treatment during immunosuppres-




Reagents were obtained from the following sources:
CHAPS (3-[(3-cholamidopropyl)- dimethylammonio]-1-
propanesulfonate) was from Pierce (Rockford, IL, USA);
nitrocellulose membrane (0.45 microns) was from Schlei-
cher and Schuell Bioscience Inc. (Keene, NH, USA);
autoradiography film (HyBlot CL) was from Denville
Scientific Inc. (Metuchen, NJ, USA); reagents for enhanced
chemiluminescence (ECL) (Immobilon Western-Chemilu-
minescent HRP Substrate) were from Upstate/Millipore
(Billerica, MA, USA); all standard chemicals were from
either Fisher Chemicals (Pittsburgh, PA, USA), Calbio-
chem/EMD Chemicals (Gibbstown, NJ, USA), or Sigma-
Aldrich (St. Louis, MI, USA).
Antibodies
The following antibodies were purchased from Cell Sig-
naling Technology (Danvers, MA, USA): P-S6K1-T389
(rabbit monoclonal 108D2); P-mTOR-S2481, HSL, ATGL,
MGL. The perilipin antibody was from Chemicon/Milli-
pore (Billerica, MA, USA) (#AB10200), and the b-actin
monoclonal antibody was from Sigma-Aldrich (St. Louis,
MI, USA). Antibodies to detect the phosphorylation of
PKA on its regulatory subunits RIIa (S96) and RIIb (S114)
were from Upstate/Millipore (Billerica, MA, USA). Cus-
tom, affinity-purified anti-peptide antibodies against
mTOR and S6K1 were generated in rabbits, as described
[7]. Sheep anti-mouse antibodies and donkey anti-rabbit
HRP secondary antibodies were from GE-Healthcare
(Piscataway, NJ, USA).
Differentiation of 3T3-L1 Fibroblasts into Adipocytes
3T3-L1 fibroblasts (kindly provided by Dr. Ormond Mac-
Dougald; University of Michigan Medical School) were
cultured in Dulbecco’s Modified Eagle Medium (DMEM)
that contained high glucose (4.5 g/L), glutamine (584 mg/
L), and sodium pyruvate (110 mg/L) supplemented with
10% newborn calf serum (NCS) (Gibco/Invitrogen;
Carlsbad, CA, USA) and maintained at 37 C in 5% CO2.
3T3-L1 fibroblasts were differentiated into adipocytes by a
standard protocol. Briefly, differentiation was induced 2
days post confluency by the addition of DMEM containing
10% fetal bovine serum (FBS) (Hyclone) and dexametha-
sone (1 lM) (Sigma-Aldrich; St. Louis, MO, USA),
3-isobutyl-1-methylxanthine IBMX (0.5 mM) (Sigma-
Aldrich; St. Louis, MI, USA) and insulin (100 nM) (Gibco/
Invitrogen; Carlsbad, CA, USA) for 2 days. The cells were
further incubated with DMEM/FBS supplemented with
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insulin for an additional 2 days. Fully differentiated adi-
pocytes were maintained in DMEM/FBS at 37 C in a
humidified atmosphere containing 5% CO2 and used 9–14
days after the initiation of differentiation.
Cell Culture, Drug Treatment, Cell Lysis and Western
Immunoblotting
3T3-L1 adipocytes were serum deprived for 20 h via
incubation in DMEM supplemented with 20 mM Hepes
(pH 7.2). Following serum deprivation, adipocytes were
drug treated for 30 min by the addition of rapamycin
(20 ng/mL) (22 nM) (Calbiochem/EMD Chemicals; Gib-
bstown, NJ, USA), or wortmannin (100 nM) (Upstate/
Millipore; Billerica, MA, USA) prior to the addition of the
b-adrenergic agonist isoproterenol (10 lM) (Chemicon/
Millipore; Billerica, MA, USA) unless indicated otherwise,
insulin (100 nM) (Invitrogen; Carlsbad, CA, USA), or both
for 30 min. For cell lysis, adipocytes were washed 29 with
ice cold PBS [pH 7.4] and collected in ice cold lysis Buffer
A (10 mM KPO4 [pH 7.2]; 1 mM EDTA; 5 mM EGTA;
10 mM MgCl2; 50 mM b-glycerophosphate; 1 mM sodium
orthovanadate (Na3VO4); 5 lg/mL pepstatin A; 10 lg/mL
leupeptin; 40 lg/mL PMSF) containing the detergent
CHAPS (0.3%). Lysates were spun at 13,200 rpm for
5 min at 4 C, and the post-nuclear supernatants were
collected. Bradford assay was used to normalize protein
levels for the measurement of triacylglycerol content,
lipolysis, cAMP levels, and Western immunoblot analyses.
For immunoblots, whole cell lysates were resuspended in
19 sample buffer (50 mM Tris–HCl pH 6.8, 10% glycerol,
2% SDS, 2% b-mercaptoethanol, 0.02% bromophenol
blue). Samples were heated at 95 C for 5 min, resolved on
SDS–PAGE gels, and transferred to nitrocellulose mem-
brane using Towbin transfer buffer (25 mM Tris; 192 mM
glycine; 10% methanol; 0.02% SDS). Immunoblotting was
performed by blocking membranes in TBST (40 mM Tris–
HCl pH 7.5; 0.9% NaCl; 0.1% Tween-20) containing 3%
nonfat milk and incubating the membranes in TBST with
2% BSA containing primary antibodies or secondary HRP-
conjugated antibodies. Blots were developed by enhanced
chemiluminescence (ECL).
Measurement of Cellular Triacylglycerol Content
Adipocyte triacylglycerol concentrations were measured by
enzymatic methods following manufacturer instructions
(Wako Chemicals, Inc.; Richmond, VA, USA) following
cellular lysis and normalization of protein content. Briefly,
samples and a set of triolein standards were incubated with
triacylglycerol reagent A at 37 C for 5 min followed by
addition of triacylglycerol reagent B for 5 min at 37 C.
The colorimetric reaction was then measured at wavelength
590 nm and expressed as mg/mg protein.
Lipolysis Assays
Following serum deprivation and drug treatment, differ-
entiated 3T3-L1 adipocytes were stimulated with isopro-
terenol for either 1 h or 4 h, as indicated in the figure
legends. The media was collected and analyzed for free
fatty acid release in the culture media using a NEFA C
assay (Wako Chemicals; Richmond, VA, USA) and read
by a spectrophotometer at wavelength 540 nm. Free fatty
acid release was measured in millimole per microgram
protein (mmol/ug) and expressed as relative free fatty acid
percent. Glycerol release in the media was measured by
colorimetric assay at wavelength 540 nm using a Chem-
icon lipolysis kit, following the manufacturer’s instructions
(Chemicon/Millipore; Billerica, MA, USA).
Measurement of Cellular cAMP Levels
Following serum deprivation, drug treatment, and isopro-
terenol stimulation, cAMP levels were measured using a
HitHunter cAMP EFC (enzyme fragment complementa-
tion) assay (Amersham/GE-Healthcare; Piscataway, NJ,
USA) following the manufacturer’s instructions. All sam-
ples and standards were run in triplicates, and lumines-
cence was detected using a multimode microplate reader
(PerkinElmer, VICTOR 3; Waltham, MA, USA).
Statistics
ANOVA (Analysis of Variance) was used to determine
overall statistical significance among various treatment
groups. If significance was achieved at P \ 0.05, then post-
hoc secondary LSD (Least Significant Difference) tests
were performed.
Results
Insulin-Mediated Activation of mTORC1 Promotes
Triacylglycerol Accumulation in 3T3-L1 Adipocytes
To determine whether mTORC1 signaling controls triac-
ylglycerol (TAG) content in adipocytes, we differentiated
3T3-L1 fibroblasts into adipocytes and treated them with
insulin in the absence or presence of rapamycin for 18 h
after a period of serum deprivation. As expected, chronic
insulin treatment promoted triacylglycerol storage
(Fig. 1a). We found that rapamycin treatment reduced
insulin-stimulated TAG accumulation *50% in a statisti-
cally significant manner (P \ 0.05), thus demonstrating
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that mTORC1 signaling is required for insulin-stimulated
TAG storage. To confirm that insulin mediated the acti-
vation of mTORC1 and downstream signaling in a rapa-
mycin-sensitive manner in this experiment, we
immunoblotted whole cell lysates with mTOR P-S2481 and
S6K1 P-T389 antibodies (Fig. 1b). Upon activation, mTOR
autophosphorylates on S2481; thus, mTOR P-S2481
immunoblotting monitors intrinsic mTOR catalytic activity
[7]. Activated mTORC1 then directly phosphorylates S6K1
on T389 [26]; thus, S6K1 P-T389 immunoblotting moni-
tors mTORC1 downstream signaling. As rapamycin
inhibited insulin-stimulated autophosphorylation of mTOR
on S2481 and the phosphorylation of S6K1 on T389, these
data indicate that rapamycin indeed inhibited the insulin-
stimulated activation of mTORC1.
Rapamycin Augments b-Adrenergic-Stimulated
Lipolysis in 3T3-L1 Adipocytes
As we found that rapamycin-mediated inhibition of
mTORC1 signaling reduces cellular TAG content, we next
asked whether rapamycin reduces TAG content by pro-
moting lipolytic rate. As the insulin/PI3K pathway pro-
motes mTORC1 signaling and also suppresses lipolysis (via
Akt-mediated activation of phosphodiesterase [PDE], an
enzyme that hydrolyzes cAMP to AMP) [27], we measured
adipocyte lipolysis in the absence of serum growth factors
in order to study lipolysis independently of PDE action. To
stimulate lipolysis, we employed the catecholamine iso-
proterenol, a synthetic b2-adrenergic agonist. By treating
serum deprived 3T3-L1 adipocytes with isoproterenol in the
absence or presence of rapamycin, we found that inhibition
of mTORC1 signaling augments isoproterenol stimulated
lipolysis in a statistically significant manner, as measured
by the release of FFA (Fig. 2a) into the cell culture media
after 1 h of incubation. Based on our preliminary kinetic
data (data not shown) as well as reported literature [28], a
1-h time point was optimal for measurements of glycerol
release (Fig. 2b) while a 4-h time point was optimal for
measurements of FFA release. We thus next measured FFA
release utilizing a 4-h time point to determine whether
mTORC1 inhibition with rapamycin augments basal lipol-
ysis, whether insulin suppresses isoproterenol-stimulated
lipolysis, and whether mTORC1 inhibition using the PI3K
inhibitor wortmannin augments isoproterenol-stimulated
lipolysis (similar to rapamycin). We found that rapamycin
had no effect on basal lipolysis after 4 h of incubation,
while, insulin indeed suppressed isoproterenol-stimulated
lipolysis, as expected (Fig. 2c). Interestingly, mTORC1
inhibition with rapamycin rescued the suppression of
lipolysis caused by insulin, suggesting a novel role for
mTORC1 in suppression of lipolysis via the insulin/Akt/
PDE pathway (Fig. 2c). Similar to rapamycin, wortmannin
treatment augmented isoproterenol-stimulated lipolysis,
suggesting a novel role for PI3K as well as mTORC1 in
suppression of lipolysis (Fig. 2c). The finding that inhibi-
tion of PI3K with wortmannin phenocopies rapamycin
treatment to augment isoproterenol-stimulated lipolysis is
consistent with the well-known regulation of mTORC1 by
PI3K [3]. These data suggest that the PI3K/mTORC1
pathway mediates lipolytic suppression.
Rapamycin Does Not Modulate Cellular cAMP Levels
To begin to understand the mechanism by which mTORC1
inhibition augments isoproterenol-stimulated lipolysis, we
Fig. 1 Insulin-stimulated triacylglycerol (TAG) accumulation in
3T3-L1 adipocytes requires mTORC1 signaling. a 3T3-L1 adipocytes
were serum-deprived for 20 h (Control) and then pre-treated without
or with rapamycin (20 ng/mL) for 30 min. Cells were stimulated
without (Control) or with insulin (INS) (100 nM) in the absence
(R) or continued presence of rapamycin (R ? INS) for 18 h. Whole
cell lysates were analyzed for triacylglycerol content (mg/mg protein)
via a colorimetric assay (see ‘‘Experimental Procedures’’) after
normalization for protein content. The graph represents the
mean ± SD of triplicate samples from one experiment but is
representative of three independent experiments; thus, each bar
represents n = 3. Differences between treatment groups were
analyzed using ANOVA, and differences were considered statistically
different at a level of 0.05. Bars with different letters are statistically
significant. b The whole cell lysates analyzed in (a) were resolved on
SDS–PAGE and immunoblotted with the indicated antibodies to
confirm the expected activation and/or inhibition of mTORC1
signaling
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determined whether rapamycin augments isoproterenol-
stimulated production of cAMP. Studies in yeast have
shown that TOR may function upstream of PKA [29], thus
lending support to such a hypothesis. We thus measured
cellular levels of cAMP in adipocytes stimulated with
isoproterenol in the absence or presence of rapamycin for
15 min (Fig. 3a) and 30 min (Fig. 3b). We found that
rapamycin treatment had no effect on cAMP levels during
basal or catecholamine-stimulated lipolysis. Thus, these
data suggest that mTORC1 inhibition does not augment
catecholamine-stimulated lipolysis by leading to increased
levels of cAMP.
Rapamycin Does Not Affect PKA Phosphorylation
To begin to study the regulation of PKA activity in intact
cells, we investigated the phosphorylation of PKA on its
regulatory subunits, RIIa (S96) and RIIb (S114), utilizing
phospho-specific antibodies. Studies have shown that
autophosphorylation of S96 on the regulatory subunit RIIa
promotes local PKA activity in cardiac muscle [30].
Additionally, point mutation of the S114 autophosphory-
lation site on RIIb has been shown to block the nuclear
localization of PKA and to inhibit PKA function in T cells
both in vitro [31] and in vivo [32]. We found that isopro-
terenol-stimulated PKA phosphorylation on regulatory
subunit RIIa (S96) or regulatory subunit RIIb (S114) was
not altered by rapamycin treatment at various isoproterenol
concentrations (Fig. 4a). While by no means conclusive,
these data suggest that mTORC1 inhibition may promote
isoproterenol-stimulated lipolysis downstream of PKA.
Alternatively, it remains possible that mTORC1 inhibition
inhibits PKA activity via a mechanism independent of
regulatory subunit phosphorylation.
Rapamycin Modestly Augments the Phosphorylation
of HSL
To determine whether PKA signaling and mTORC1 inhi-
bition synergistically modulate the activation state of
lipolytic targets, we assayed the phosphorylation of two
well known PKA dependent targets, hormone sensitive
lipase (HSL) and perilipin. In response to starvation and
stress, catecholamine induced activation of the cAMP/PKA
pathway leads to PKA-mediated phosphorylation of both
perilipin and HSL [23]. PKA-induced phosphorylation of
perilipin on at least 6 sites triggers a conformational change
Fig. 2 Inhibition of mTORC1 with rapamycin augments b-adrener-
gic-activated lipolysis in 3T3-L1 adipocytes. a, b 3T3-L1 adipocytes
were serum-deprived for 20 h and then pre-treated without or with
rapamycin (R) (20 ng/mL) for 30 min. Cells were then incubated in
the absence (Basal) or presence of isoproterenol (Iso) (10 lM) for 1 h
in the absence or continued presence of rapamycin (Iso ? R).
Relative free fatty acid (FFA) release was measured in (a) and
relative glycerol release was measured in (b). In graphs (a, b) each
bar represents the mean value ± SD of 5 samples from three
independent experiments; thus, each bar represents n = 5. The value
from cells treated with Iso alone was set to 100%, and all other values
were normalized to this value. c 3T3-L1 adipocytes were treated
similarly as in (a, b) with minor modifications, and relative free fatty
acid (FFA) release was measured, as in (a). Briefly, serum-deprived
cells were pre-treated without or with rapamycin (20 ng/mL) or
wortmannin (100 nM) for 30 min. Cells were then incubated in the
absence (Basal lipolysis) or presence of isoproterenol (10 lM) for 4 h
without (Iso) or with insulin (100 nM) (Iso ? INS), rapamycin
(Iso ? R), wortmannin (Iso ? W), or both insulin and rapamycin
(Iso ? INS ? R), as indicated in the graph. Cells incubated in the
absence of isoproterenol (Basal lipolysis) were also incubated with
insulin (INS), rapamycin (R), wortmannin (W), and insulin and
rapamycin (INS ? R) for 4 h. In graph (c), each bar represents the
mean value ± SD of nine samples from three independent experi-
ments; thus, each bar represents n = 9. As in graphs (a, b), the value
of Iso alone was set to 100%, and all other values were normalized to
this value. Differences between treatment groups were analyzed using
ANOVA, and differences were considered statistically different at a
level of 0.05. Bars with different letters are statistically significant
c
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that disassembles the perilipin protective coat and induces
the translocation of HSL from the cytoplasm to the surface
of lipid droplet, whereby HSL docks to phosphorylated
perilipin [23, 33]. To determine whether rapamycin aug-
ments isoproterenol-stimulated phosphorylation of perili-
pin, we employed a commonly used SDS–PAGE mobility
shift assay to determine the phosphorylation state of per-
ilipin. Serum deprived 3T3-L1 adipocytes were pretreated
with rapamycin and then stimulated in the absence of
isoproterenol or with a series of isoproterenol concentra-
tions ranging from maximal to sub-maximal (10 lM down
to 1 nM). As expected, isoproterenol strongly promoted the
phosphorylation of perilipin in a dose-dependent manner,
as shown by decreased electrophoretic mobility on SDS–
PAGE (Fig. 4b). Rapamycin treatment had no effect on
isoproterenol-induced perilipin phosphorylation, even at
sub-maximal doses (0.1 lM, 10 nM). At the limited reso-
lution of this assay, these data suggest that mTORC1
inhibition with rapamycin does not synergize with cate-
cholamine induced PKA signaling to promote significant
phosphorylation of perilipin. Although mobility shift is a
commonly used method in detection of perilipin phos-
phorylation state, we acknowledge the possibility that
rapamycin could promote the phosphorylation of individ-
ual sites on perilipin whose phosphorylation state may not
be measurable by mobility shift. We next investigated the
phosphorylation of the lipase HSL, which functions as the
rate-limiting enzyme in the lipolytic cascade. To date, three
PKA-mediated phosphorylation sites (Ser563; Ser659;
Ser660) and one AMPK-mediated phosphorylation site
(Ser565) have been identified on rat HSL, as illustrated in
Fig. 4c [34, 35]. Phosphorylation of HSL on Ser563 by PKA
is thought to promote the intrinsic catalytic activity of HSL
[36], while phosphorylation of HSL on Ser659 and Ser660 by
PKA are thought to promote the translocation of cytosolic
HSL to the surface of the lipid droplet [23]. Conversely,
phosphorylation of HSL on Ser565 by AMPK is thought to
inhibit HSL activity [37]. By treating 3T3-L1 adipocytes
with various concentrations of isoproterenol in the absence
and presence of rapamycin, we found that rapamycin
augmented HSL Ser563 phosphorylation (Fig. 4c). On the
contrary, there was no additional effect of rapamycin on
isoproterenol-stimulated phosphorylation of HSL Ser660
(Fig. 4c). Neither isoproterenol nor rapamycin modulated
AMPK Ser565 phosphorylation, which appears to be con-
stitutively activated under basal conditions [37]. Taken
together, these data indicate that mTORC1 inhibition with
rapamycin synergizes with PKA signaling to augment the
phosphorylation of HSL on Serine 563, which may accel-
erate lipolysis by augmenting HSL catalytic activity.
Rapamycin Has No Effect on ATGL, HSL, or MGL
Protein Expression
To determine whether mTORC1 inhibition with rapamycin
additionally promotes lipolysis by modulating the expres-
sion of the lipases critical for the breakdown of TAG into
FFAs and glycerol, we examined the protein expression of
adipose triacylglycerol lipase (ATGL), hormone sensitive
lipase (HSL), and monoacyl lipase (MGL). It is currently
believed that ATGL initiates basal as well as hormone
sensitive lipolysis of triacylglycerol [38, 39] to FFA and
diacylglycerol. Subsequently, HSL acts on diacylglycerol
particles to release FFA and monoacylglycerol. The final
step in lipolysis is catalyzed by the hormone-insensitive
MGL, which acts on monoacylglycerol to release FFA and
glycerol [39]. Some investigators [40] also suggest a role
for triacylglycerol hydrolase (TGH) in lipolysis; the rela-
tive contribution of TGH in the lipolytic cascade within the
Fig. 3 Rapamycin does not augment cAMP levels over b-adrenergic
agonist alone. cAMP levels were measured using the HitHunter
cAMP EFC chemiluminescent detection assay (Amersham, Inc.),
according to manufacturer’s directions. Briefly, 3T3-L1 adipocytes
were serum deprived 20 h and pre-treated without or with rapamycin
(R) (20 ng/mL) for 30 min. Cells were then incubated in the absence
(DMEM) or presence of isoproterenol (Iso) (1 lM or 10 lM) for
15 min (a) or (10 lM) 30 min (b) in the absence or presence of
rapamycin (Iso ? R). ‘‘No ED’’ (without enzyme donor) and ‘‘PBS’’
represent negative controls for this assay. Bars with different letters
are statistically significant at a level of 0.05
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adipocyte remains unclear, however. We treated 3T3-L1
adipocytes with isoproterenol in the absence or presence of
rapamycin for 18 h and measured the protein expression of
ATGL, HSL, and MGL by immunoblot (Fig. 5). We found
no differences in the abundance of these 3 important
lipases under any treatment condition. Thus, these data
indicate that mTORC1 inhibition with rapamycin does not
augment lipolytic rate by increasing the expression of a
critical lipase.
Discussion
Here, we investigated the biochemical mechanism by
which mTORC1 inhibition via the immunosuppressive
drug rapamycin induces hypertriglyceridemia and increases
circulating free FFAs in organ transplant patients [11] as
well as in guinea pigs [25]. We report that treatment of
3T3-L1 adipocytes with the mTORC1 inhibitor rapamycin
decreases TAG storage by augmenting lipolysis induced by
Fig. 4 Rapamycin augments isoproterenol-stimulated phosphoryla-
tion of HSL on S563 in the absence of effects on PKA regulatory
subunit or perilipin phosphorylation. a Rapamycin does not modulate
the phosphorylation of PKA on the regulatory subunits RIIa (S196) or
RIIb (S114): 3T3-L1 adipocytes were serum-deprived for 20 h and
then pre-treated without (-) or with (?) rapamycin (20 ng/mL) for
30 min. Cells were incubated in the absence (-) or presence of
various concentrations of isoproterenol (Iso) ranging from 10 lM to
1 nM for 15 min, as indicated. After lysis, whole cell lysate was
resolved on SDS–PAGE and immunoblotted with the indicated
antibodies. b Rapamycin does not augment isoproterenol-stimulated
phosphorylation of perilipin: 3T3-L1 adipocytes were serum-deprived
for 20 h and pre-treated without (-) or with (?) rapamycin (Rapa)
(20 ng/mL) for 30 min. Cells were then incubated in the absence (-)
or presence (?) of isoproterenol (Iso) (10 lM) in the absence or
presence of rapamycin for 15 min. After lysis, whole cell lysate was
resolved on SDS–PAGE and immunoblotted with perilipin antibodies.
Note: To observe perilipin electrophoretic mobility shift, a measure of
perilipin phosphorylation, a 21 cm long 8% gel was run for 3:30 h. To
visualize total perilipin, a 13-cm long 12% gel was run for 1:45 h.
c Rapamycin augments isoproterenol-stimulated phosphorylation of
HSL on S563 (a PKA phosphorylation site) but not on S565 (an
AMPK phosphorylation site): Upper panel: Schematic of the HSL
sites phosphorylated by PKA and AMPK. Lower panel: 3T3-L1
adipocytes were serum-deprived and pre-treated without (-) or with
(?) rapamycin, as in (a, b) above. Cells were then incubated in the
absence (-) or presence of various concentrations of isoproterenol
(Iso) ranging from 10 lM to 1 nM for 15 min, as indicated. After
lysis, whole cell lysates were resolved on SDS–PAGE and immuno-
blotted with the indicated antibodies. Cells were also lysed imme-
diately after serum deprivation (Basal). Two P-HSL-S563 film
exposures are shown (SE-short exposure, LE-long exposure)
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isoproterenol, a b-adrenergic agonist, without altering
basal lipolysis. While, the measured effect of rapamycin on
hormone-induced lipolysis was modest, the combined
effect of increased lipolysis and decreased TAG synthesis
incurred by mTOR inhibition likely has a more significant
impact on TAG metabolism. Our data further elucidate the
mechanism by which mTORC1 inhibition cooperates with
PKA signaling to promote lipolysis: We found that rapa-
mycin augments isoproterenol-induced phosphorylation of
HSL (on S563) via a mechanism that does not involve
increased production of cAMP. These data indicate that
mTORC1 inhibition and PKA signaling synergize either
downstream of PKA or at the level of PKA to promote
lipolysis (Fig. 6). Whether, mTORC1 inhibition and PKA
converge on common lipolytic targets (e.g. HSL, ATGL)
via parallel pathways or, whether mTORC1 inhibition
converges on PKA itself to enhance its function (via
increased enzymatic activity, altered subcellular localiza-
tion, etc.) remains currently unknown (see model in
Fig. 6). In support of the former model, TOR and PKA
signal via parallel pathways in budding yeast to regulate
the transcriptional expression of ribosomal protein genes
and stress-responsive genes [41]. In support of the latter
model, TORC1 signaling in budding yeast was reported
recently to regulate PKA activity [42]. Lastly, we found
that rapamycin treatment (18 h) had no effect on the
expression of various lipases, including ATGL, HSL, or
MGL under basal or isoproterenol-stimulated conditions.
Our data are consistent with the recent work of Chak-
rabarti et al., who showed that inhibition of mTORC1
signaling via rapamycin or knockdown of the critical
mTORC1 partner raptor decreases TAG storage by
increasing lipolysis in 3T3-L1 adipocytes [43]. Consis-
tently, this work demonstrated that overexpression of the
mTORC1 activator Rheb augments TAG storage and
suppresses lipolysis [43]. Our data differ in that Chakrab-
arti et al. found that rapamycin also modestly augments
Fig. 5 Rapamycin does not modulate the protein expression of
ATGL, HSL, or MGL. 3T3-L1 adipocytes were serum-deprived for
20 h (lanes 1–5) and pre-treated without (lanes 1–2, 5) or with (lanes
3, 4) rapamycin (R) (20 ng/mL) for 30 min. Cells were then
incubated in the absence (-) (lanes 2–3) or presence (?) (lanes
4–5) of isoproterenol (10 lM) for 18 h in the absence or continued
presence of rapamycin, as indicated. In lane 1, cells were lysed after
the 20 h serum deprivation period (t = 0). In lane 6, cells were
cultured in DMEM/10% FBS (steady-state, non-starved conditions).
After lysis, whole cell lysate was resolved on SDS–PAGE and
immunoblotted with the indicated antibodies
Fig. 6 Model for the role of mTORC1 signaling in suppression of
lipolysis in adipocytes. The b-adrenergic agonist isoproterenol, a
synthetic catecholamine, promotes triacylglycerol (TAG) breakdown
(lipolysis) by activating a large heterotrimeric Gas-protein that
activates adenylate cyclase (AC), which converts ATP into cAMP.
cAMP binds the regulatory subunits of protein kinase (PKA), thus
dissociating the repressive regulatory subunits from the catalytic
subunits. Catalytically active PKA phosphorylates downstream
targets, including perilipin and hormone sensitive lipase (HSL),
which contribute to initiation of lipolysis together with several other
lipases including ATGL (adipose triacylglycerol lipase) and MGL
(monoacyl lipase), ultimately leading to the breakdown of TAG into
free fatty acids (FFA) and glycerol. mTORC1 signaling suppresses
lipolysis by either acting on common lipolytic targets (e.g., HSL,
others?) via a pathway parallel to PKA or by converging on PKA to
inhibiting its function. By inhibiting mTORC1 signaling, rapamycin
synergizes with the PKA pathway to promote lipolysis, thus reducing
TAG storage; therefore, mTORC1 signaling suppresses lipolysis, thus
augmenting TAG storage
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basal lipolysis and modestly reduces the mRNA and pro-
tein expression of the lipase ATGL [43]. We found no
evidence for alterations in basal lipolytic rate or ATGL
expression upon rapamycin treatment. Perhaps differences
in experimental conditions account for these apparent
discrepancies.
Emerging data identify mTORC1 an important novel
controller of both anabolic and catabolic lipid metabolism
by regulating lipogenesis and lipolysis, respectively [44,
45]. mTORC1 signaling induces adipogenic differentiation
and maintains the adipogenic program by promoting the
expression and activation state of the transcription factor
PPARc (peroxisome proliferator-activated receptor-c), a
nuclear hormone receptor that induces the expression of
genes that promote fatty acid uptake, synthesis, esterifica-
tion, and storage [46]. Moreover, mTORC1 signaling
promotes lipid biosynthesis by cleaving the transcription
factor SREBP-1 (sterol regulatory element binding protein-
1) into a mature form that translocates to the nucleus to
induce the expression of lipogenic genes that promote fatty
acid and TAG synthesis [45, 47].
As increased levels of circulating FFA are well docu-
mented as an etiological factor in the development of
insulin resistance, the cumulative data suggest that rapa-
mycin administration to patients may exacerbate insulin
resistance by promoting TAG lipolysis [48]. Indeed, stud-
ies in a diabetic rodent model showed that injection of
rapamycin led to worsened hyperglycemia and diabetes
[48]. Impaired TOR signaling also appears to promote
lipolysis in model organisms. For example, in Drosophila,
loss-of-function mutations in melted leads to decreased
dTOR signaling and a 10% decrease in animal size, con-
sistent with a role of mTOR in cell growth control; strik-
ingly, melted flies possess 40% less fat relative to control
animals in the fat body, the primary energy storage
organ [49]. This phenotype is fat-body autonomous, as
re-expression of wild type melted in the fat body rescues
the leanness of melted mutants [49]. Additionally, global
knockout of the mTORC1 substrate S6K1 in mice produces
animals with increased levels of plasma FFA that exhibit
mild glucose intolerance and resistance to diet-induced
obesity [14, 50]. Consistently, increased mTORC1 signal-
ing to eukaryotic initiation factor 4E (eIF4E) via global
knockout of the eIF4E inhibitors 4EBP-1 and 4EBP-2 leads
to increased adipogenesis, decreased lipolysis, and
increased FFA re-esterification, which cooperatively
induce obesity [51].
In conclusion, these data demonstrate that cellular
inhibition of mTORC1 signaling with rapamycin, as well
as inhibition of PI3K with wortmannin, synergizes with the
PKA pathway to augment the phosphorylation of HSL
leading to enhanced hormone-induced lipolysis. Thus,
mTORC1 signaling antagonizes the PKA pathway to
suppress hormone-induced lipolysis. Many questions
remain regarding the molecular mechanism by which
mTORC1 signaling impacts lipolytic targets. Does
mTORC1 directly or indirectly (via downstream substrates)
antagonize PKA signaling? Does mTORC1 signaling
suppress PKA activity or does mTORC1 signal along a
parallel pathway that converges on a common lipolytic
target that lies downstream of PKA? Our data and that of
others reveal a novel role for PI3K/mTORC1 signaling in
control of cellular TAG and FFA metabolism: mTORC1
signaling reduces lipolytic rate, thus promoting TAG
storage. Elucidating the molecular mechanisms by which
mTORC1 signaling modulates lipid metabolism may
enable clinicians in the future to better manage the dele-
terious side effects incurred by therapeutic rapamycin or
analog treatment employed for immunosuppression, stent
restenosis, and cancer. Additionally, as altered lipid
homeostasis contributes to diverse human diseases
including type II diabetes, obesity, cancer, and cardiovas-
cular disease, elucidation of the biochemical mechanisms
by which mTORC1 signaling modulates lipid metabolism
is important both biologically and clinically.
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